Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEK | Q02763 | 6/20 | 0.70 |
| ▸ | KDR | P35968 | 5/20 | 0.70 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.66 |
| ▸ | AURKB | Q96GD4 | 10/20 | 0.58 |
| ▸ | AURKA | O14965 | 5/20 | 0.58 |
| ▸ | TPX2 | Q9ULW0 | 3/20 | 0.58 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.52 |
| ▸ | AKT1 | P31749 | 1/20 | 0.52 |
| ▸ | PLK1 | P53350 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL973732 | 0.89 | TEK (0.62) | TEKKDRPDE10AAURKBAURKA | |
| SCHEMBL972856 | 0.87 | TEK (0.71) | TEKKDRPDE10AAURKBAURKA | |
| SCHEMBL972094 | 0.86 | TEK (0.54) | TEKKDRPDE10AAURKBAURKA | |
| SCHEMBL581474 | 0.81 | TEK (0.68) | TEKAURKBAURKATPX2 | |
| SCHEMBL973158 | 0.80 | PDE10A (0.72) | TEKKDRPDE10AAURKBAURKA | |
| SCHEMBL2489700 | 0.80 | PDE10A (1.00) | PDE10ANPC1RAB9A | |
| SCHEMBL2491583 | 0.80 | PDE10A (0.71) | TEKKDRPDE10AAURKBPTK2 | |
| SCHEMBL974603 | 0.79 | AURKB (0.70) | TEKKDRPDE10AAURKBAURKA | |
| SCHEMBL974493 | 0.79 | TEK (1.00) | TEKKDRPDE10AAURKBAURKA | |
| SCHEMBL2490606 | 0.79 | PDE10A (1.00) | PDE10ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868177-B2 | Multi-cyclic compounds and method of use | AMGEN INC. (US) | 2011-01-11 | — | — | US | claimed |
| EP-1994030-B1 | MULTI-CYCLIC COMPOUNDS AND METHOD OF USE | AMGEN INC (US) | 2010-08-25 | — | — | EP | claimed |
| EP-1994030-A1 | MULTI-CYCLIC COMPOUNDS AND METHOD OF USE | Amgen Inc. (US) | 2008-11-26 | — | — | EP | claimed |
| US-20070213325-A1 | Multi-cyclic compound and method of use | AMGEN INC. (US) | 2007-09-13 | — | — | US | claimed |
| WO-2007100646-A1 | MULTI-CYCLIC COMPOUNDS AND METHOD OF USE | AMGEN INC. (US) | 2007-09-07 | — | — | WO | claimed |
| EP-1994030-B1 | MULTI-CYCLIC COMPOUNDS AND METHOD OF USE | AMGEN INC (US) | 2010-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213325-A1 | Multi-cyclic compound and method of use | TIE1, CDK1, CCNB1 | TEK 22/4885KDR 12/4885PDE10A 2613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.